Tags

Type your tag names separated by a space and hit enter

Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure.
Br J Pharmacol. 2003 Jan; 138(2):301-9.BJ

Abstract

1. We examined the effects of eprosartan, an AT(1) receptor antagonist, on the progression of left ventricular (LV) dysfunction and remodelling in dogs with heart failure (HF) produced by intracoronary microembolizations (LV ejection fraction, EF 30 to 40%). 2. Dogs were randomized to 3 months of oral therapy with low-dose eprosartan (600 mg once daily, n=8), high-dose eprosartan (1200 mg once daily, n=8), or placebo (n=8). 3. In the placebo group, LV end-diastolic (EDV) and end-systolic (ESV) volumes increased after 3 months (68+/-7 vs 82+/-9 ml, P<0.004, 43+/-1 vs 58+/-7 ml, P<0.003, respectively), and EF decreased (37+/-1 vs 29+/-1%, P<0.001). In dogs treated with low-dose eprosartan, EF, EDV, and ESV remained unchanged over the course of therapy, whereas in dogs treated with high-dose eprosartan, EF increased (38+/-1 vs 42+/-1%, P<0.004) and ESV decreased (41+/-1 vs 37+/-1 ml, P<0.006), Eprosartan also decreased interstitial fibrosis and cardiomyocyte hypertrophy. 4. We conclude that eprosartan prevents progressive LV dysfunction and attenuates progressive LV remodelling in dogs with moderate HF and may be useful in treating patients with chronic HF.

Authors+Show Affiliations

Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Heart & Vascular Institute, Detroit, Michigan 48202, U.S.A.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12540520

Citation

Suzuki, George, et al. "Effects of the AT1-receptor Antagonist Eprosartan On the Progression of Left Ventricular Dysfunction in Dogs With Heart Failure." British Journal of Pharmacology, vol. 138, no. 2, 2003, pp. 301-9.
Suzuki G, Mishima T, Tanhehco EJ, et al. Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. Br J Pharmacol. 2003;138(2):301-9.
Suzuki, G., Mishima, T., Tanhehco, E. J., Sharov, V. G., Todor, A., Rostogi, S., Gupta, R. C., Chaudhry, P. A., Anagnostopoulos, P. V., Nass, O., Goldstein, S., & Sabbah, H. N. (2003). Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. British Journal of Pharmacology, 138(2), 301-9.
Suzuki G, et al. Effects of the AT1-receptor Antagonist Eprosartan On the Progression of Left Ventricular Dysfunction in Dogs With Heart Failure. Br J Pharmacol. 2003;138(2):301-9. PubMed PMID: 12540520.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. AU - Suzuki,George, AU - Mishima,Takayuki, AU - Tanhehco,Elaine J, AU - Sharov,Victor G, AU - Todor,Anastassia, AU - Rostogi,Sharad, AU - Gupta,Ramesh C, AU - Chaudhry,Pervaiz A, AU - Anagnostopoulos,Petros V, AU - Nass,Omar, AU - Goldstein,Sidney, AU - Sabbah,Hani N, PY - 2003/1/24/pubmed PY - 2003/8/5/medline PY - 2003/1/24/entrez SP - 301 EP - 9 JF - British journal of pharmacology JO - Br. J. Pharmacol. VL - 138 IS - 2 N2 - 1. We examined the effects of eprosartan, an AT(1) receptor antagonist, on the progression of left ventricular (LV) dysfunction and remodelling in dogs with heart failure (HF) produced by intracoronary microembolizations (LV ejection fraction, EF 30 to 40%). 2. Dogs were randomized to 3 months of oral therapy with low-dose eprosartan (600 mg once daily, n=8), high-dose eprosartan (1200 mg once daily, n=8), or placebo (n=8). 3. In the placebo group, LV end-diastolic (EDV) and end-systolic (ESV) volumes increased after 3 months (68+/-7 vs 82+/-9 ml, P<0.004, 43+/-1 vs 58+/-7 ml, P<0.003, respectively), and EF decreased (37+/-1 vs 29+/-1%, P<0.001). In dogs treated with low-dose eprosartan, EF, EDV, and ESV remained unchanged over the course of therapy, whereas in dogs treated with high-dose eprosartan, EF increased (38+/-1 vs 42+/-1%, P<0.004) and ESV decreased (41+/-1 vs 37+/-1 ml, P<0.006), Eprosartan also decreased interstitial fibrosis and cardiomyocyte hypertrophy. 4. We conclude that eprosartan prevents progressive LV dysfunction and attenuates progressive LV remodelling in dogs with moderate HF and may be useful in treating patients with chronic HF. SN - 0007-1188 UR - https://www.unboundmedicine.com/medline/citation/12540520/Effects_of_the_AT1_receptor_antagonist_eprosartan_on_the_progression_of_left_ventricular_dysfunction_in_dogs_with_heart_failure_ L2 - https://doi.org/10.1038/sj.bjp.0705032 DB - PRIME DP - Unbound Medicine ER -